Get to know our clinical trials
Trial evaluating combined oral fecal microbiotherapy MaaT033 to prevent complications of allogeneic hematopoietic cell transplantation.
MAAT PHARMA (THE DEVELOPER) IS CONDUCTING A RESEARCH STUDY TO DETERMINE WHETHER AN EXPERIMENTAL DRUG THAT HAS NOT YET RECEIVED MARKETING AUTHORIZATION, CALLED MAAT033, WILL HELP PREVENT COMPLICATIONS THAT CAN OCCUR AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION, IMPROVE SURVIVAL AND HOW SAFE IT IS FOR USE IN HUMANS.
Technical Summary
- PHASE IIB, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, MULTICENTER, DOUBLE-BLINDED, PHASE IIB TRIAL EVALUATING COMBINED ORAL FECAL MICROBIOTHERAPY MAAT033 TO PREVENT COMPLICATIONS OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION.
- Code EudraCT: 2022-00501831-18-00
- Protocol number: MPOH08
- Promoter: Maat Pharma
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
More information about this clinical trial
Information offered by the Spanish Registry of Clinical Studies
- Summary
- Information
- Calendar
- Headquarters
- Drugs
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.